Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.

For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.